Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.

CONCLUSION: We developed an IHC-based approach to classify TNBCs into molecular subtypes. This IHC-based classification can provide additional information for prognostic evaluation. It allows for subgrouping of TNBC patients in large clinical trials and evaluating the efficacy of targeted therapies within certain subtypes. It has potential to be routinely used to guide treatment decisions for patients with TNBC.
IMPLICATIONS FOR PRACTICE: We developed an immunohistochemistry (IHC)-based classification approach for triple-negative breast cancer (TNBC), which exhibited substantial agreement with the mRNA expression-based classification. The implications for practice are as follows. Our IHC-based classification (a) allows for subgrouping of TNBC patients in large clinical trials and evaluating the efficacy of targeted therapies within certain subtypes, (b) will contribute to the practical application of subtype-specific treatment for patients with TNBC, and (c) can provide additional information beyond traditional prognostic factors in relapse prediction.
PMID: 32406563 [PubMed - as supplied by publisher]

Source: The Oncologist - May 13, 2020 Category: Cancer & Oncology Authors: Zhao S, Ma D, Xiao Y, Li XM, Ma JL, Zhang H, Xu XL, Lv H, Jiang WH, Yang WT, Jiang YZ, Zhang QY, Shao ZM Tags: Oncologist Source Type: research